Silexion Therapeutics to participate in September 2026 industry conferences
Silexion Therapeutics announced management will participate in September 2026 Industry and Investor Conferences. The company is a clinical-stage biotechnology focused on RNA interference (RNAi) therapies for KRAS-driven cancers.